A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke
NEJM 382:9-19,81, Amarenco, P.,et al, 2020
Diagnosis and Management of the Antiphospholipid Syndrome
NEJM 378:2010-2021, Garcia, D. & Erkan, D., 2018
Factor Xa Inhibitors Versus Vitamin K Antagonists for Prevention of Cerebral or Systemic Embolism in Patients with Atrial Fibrillation
Stroke 49:e235-e236, Bruins Slot, K.M.H. & Berge, E., 2018
Patent Foramen Ovale Closure, Antiplatelet Therapy or Anticoagulation Therapy Alone for Management of Cryptogenic Stroke?
BMJ 362:k2515, Kuijpers, T.,et al, 2018
Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients
Stroke 47:1555-1561, Shah, A.,et al, 2016
Effect of a Cerebral Protection Device on Brain Lesions Following Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis
JAMA 316:592-601,587, Haussig, S.,et al, 2016
Stroke Prevention in Atrial Fibrillation
JAMA 313:1950-1962, Lip, G.Y.H. & Lane, D.A., 2015
Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: Current Status, Special Situations, and Unmet Needs
Lancet 386:303-310, Verheugt, F.W.A. & Granger, C.B., 2015
Intracranial Atherosclerosis
Lancet 383:984-998, Qureshi, A. & Caplan, L.R., 2014
Factor Xa Inhibitors vs Warfarin for Preventing Stroke and Thromboembolism in Patients with Atrial Fibrillation
JAMA 311:1150-1151, Bruins Slot, K.M.H. & Berge, E., 2014
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
NEJM 368:1092-1100,1152, Carroll, J.D.,et al, 2013
Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
NEJM 368:1083-1091,1152, Meier, B.,et al, 2013
Left Atrial Catheter Ablation and Ischemic Stroke
Stroke 43:265-270, Haeusler, K.G.,et al, 2012
Patent Foramen Ovale Closure and Medical Treatments for Secondary Stroke Prevention
Stroke 43:422-431, Kitsios,G.D.,et al, 2012
Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale
NEJM 366:991-999,1048, Furlan,A.J.,et al, 2012
Secondary Prevention after Ischemic Stroke or Transient Ischemic Attack
NEJM 366:1914-1922;, Davis, S.M. & Donnan, G.A., 2012
Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
Stroke 42:227-276, Furie,K.L.,et al, 2011
New Alternative to Warfarin May Help Reduce Stroke Risk in Patients With AF
JAMA 305:25-26, Mitka,M., 2011
Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data
Pharmacol Ther 129:185-194, Terry, K.W.,et al, 2011
Improved Late Survival and Disability After Stroke With Therapeutic Anticoagulation for Atrial Fibrillation
Stroke 42:2503-2508, Hannon, N.,et al, 2011
A New Landscape for Stroke Prevention in Atrial Fibrillation
Stroke 42:3316-3322, Banerjee, A.,et al, 2011
Dabigatran Challenges Warfarins Superiority for Stroke Prevention in Atrial Fibrillation
Stroke 41:1307-1309, Schwartz,N.E. &Albers,G.W., 2010
Study Design of the CLOSURE I Trial: A Prospective, Multicenter, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex Septal Closure System Versus Best Medical Therapy in Patients With Stroke or TIA Due to Presumed Paradoxical Embolism Through a PFO
Stroke 41:2872-2883, Furlan,A.J.,et al, 2010
Potentially Preventable Strokes in High-Risk Patients with Atrial Fibrillation Who Are Not Adequately Anticoagulated
Stroke 40:235-240,5, Gladstone,D.J.,et al, 2009
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
NEJM 360:2066-2078,2127, The ACTIVE Investigators, 2009
Does the Combination of Warfarin and Aspirin Have a Place in Secondary Stroke Prevention? No
Stroke 40:1944-1945,1946, Fisher,M., 2009
Does the Combination of Warfarin and Aspirin Have a Place in Secondary Stroke Prevention? Yes
Stroke 40:1942-1943,1946, Furlan,A.J., 2009
Recurrent Cerebral Ischemia in Medically Treated Patent Foramen Ovale: A Meta-Analysis
Neurol 73:89-97,84, Almekhlafi,M.A.,et al, 2009
Antithrombotic Management of Patients with Prosthetic Heart Valves: Current Evidence and Future Trends
Lancet 374:565-576, Sun,J.C.J.,et al, 2009
Who Is Ineligible for Warfarin in Atrial Fibrillation?
Lancet 374:510-511, Verheugt,F.W.A., 2009
Dabigatran Versus Warfarin in Patients with Atrial Fibrillation
NEJM 361:1139-1151, 1200, Connolly,S.,et al, 2009
Management of Stroke in Infants and Children: A Scientific Statement From a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young
Stroke 39:2644-2691, Roach,E.S.,et al., 2008
Secondary Stroke Prevention With Ximelagatran Versus Warfarin in Patients With Atrial Fibrillation: Pooled Analysis of SPORTIF III and V Clinical Trials
Stroke 38:874-880, Akins,P.T.,et al, 2007
Warfarin Versus Aspirin for Stroke Prevention in an Elderly Community Population With Atrial Fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A Randomised Controlled Trial
Lancet 370:493-503,460, Mant,J.,et al, 2007
Can Patients at Elevated Risk of Stroke Treated With Anticoagulants Be Further Risk Stratified?
Stroke 38:2459-2463,2409, Baruch,L.,et al, 2007
Antiplatelet Therapy for Preventing Stroke in Patients With Nonvalvular Atrial Fibrillation and No Previous History of Stroke or Transient Ischemic Attacks
Stroke 37:274-275, Aguilar,M.I. &Hart,R.G., 2006
Therapeutic Strategies After Examination by Transesophageal Echocardiography in 503 Patients with Ischemic Stroke
Stroke 37:859-864, Harloff,A.,et al, 2006
Clopidogrel Plus Aspirin Versus Oral Anticoagulation for Atrial Fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W): A Randomised Controlled Trial
Lancet 367:1903-1912,1877, The ACTIVE Writing Group on behalf of the ACTIVE Investigators, 2006
Early Coronary Revascularization Diminishes the Risk of Ischemic Stroke with Acute Myocardial Infarction
Stroke 37:2546-2551, vanDeGraaff,E.,et al, 2006
Anticoagulants Versus Antiplatelet Therapy for Preventing Stroke in Patients with Nonrheumatic ATrial Fibrillation and a History of Stroke or Transient Ischemic Attack
Stroke 36:914-915, Saxena,R. &Koudstaal,P.J., 2005
Ximelagatran vs Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation
JAMA 293:690-698,736, SPORTIF Executive Steering Committee for the SPORTIF V Investigators, 2005
Malignant Hyperthermia, Update on Susceptibility Testing
JAMA 293:2918-2924,2958, Litman,R.S.&Rosenberg,H., 2005
Direct Thrombin Inhibition
Stroke 35:1519-1522, Elkind,M.S.V. &Sacco,R.L., 2004
Cerebral Ischemic Events After Diagnosis of Mitral Valve Prolapse
Stroke 34:1339-1345, Avierinos,J.,et al, 2003
Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation
NEJM 349:1019-1026, Hylek,E.M.,et al, 2003
Stroke Prevention with the Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin in Patients with Non-Valvular Atrial Fibrillation (SPORTIF III): Randomised Controlled Trial
Lancet 362:1691-1698,1686, Executive Steering Committee on Behalf of the SPOR, 2003
Recent Developments in Neurology
BMJ 324:656-660, Wiebe,S.,&Nicolle,M.W., 2002
New Evidence for Stroke Prevention
JAMA 288:1388-1395, Straus,S.E.,et al, 2002
Prevalence of Atrial Fibrillation and Antithrombotic Prophylaxis in Emergency Department Patients
Stroke 33:2664-2669, Scott,P.A.,et al, 2002